对2018年国际妇产联盟宫颈癌新分期的思考

国际肿瘤学杂志››2021,Vol. 48››Issue (10): 627-630.doi:10.3760/cma.j.cn371439-20201230-00123

对2018年国际妇产联盟宫颈癌新分期的思考

牛雯娟¹, 段文杰¹, 苏雅婷¹, 魏芳²()

¹山西医科大学第二临床医学院,太原 030001
²山西医科大学第二临床医院妇科,太原030001

收稿日期:2020-12-30修回日期:2021-04-27出版日期:2021-10-08发布日期:2021-11-24
通讯作者:魏芳 E-mail:2yuanweifang@163.com
基金资助:
山西省自然科学基金(201901D111363)

Consideration on the new stage of cervical cancer revised by the International Federation of Obstetrics and Gynecology in 2018

Niu Wenjuan¹, Duan Wenjie¹, Su Yating¹, Wei Fang²()

¹Second School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, China
²Department of Gynecology, Second Clinical Hospital Affiliated to Shanxi Medical University, Taiyuan 030001, China

Received:2020-12-30Revised:2021-04-27Online:2021-10-08Published:2021-11-24
Contact:Wei Fang E-mail:2yuanweifang@163.com
Supported by:
Natural Science Foundation of Shanxi Province of China(201901D111363)

摘要/Abstract

摘要：

一套有效、可靠且实用的分期对宫颈癌的诊治有很大的帮助。宫颈癌是妇科肿瘤中一个采用临床分期的恶性肿瘤,但分期对判断肿瘤大小、宫旁浸润、阴道切缘及脉管浸润等缺乏客观性。2018年10月国际妇产联盟(FIGO)重新修订了之前一直沿用的2009年FIGO宫颈癌分期,但2018年宫颈癌新分期的变更点存在很多争议。

牛雯娟, 段文杰, 苏雅婷, 魏芳. 对2018年国际妇产联盟宫颈癌新分期的思考[J]. 国际肿瘤学杂志, 2021, 48(10): 627-630.

Niu Wenjuan, Duan Wenjie, Su Yating, Wei Fang. Consideration on the new stage of cervical cancer revised by the International Federation of Obstetrics and Gynecology in 2018[J]. Journal of International Oncology, 2021, 48(10): 627-630.

参考文献33

[1]	Zhang X, Lv Z, Xu X, et al. Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stageⅠB-ⅡA cervical cancer following radical surgery[J]. BMC Cancer, 2020, 20(1):664. DOI: 10.1186/s12885-020-07148-x. doi:10.1186/s12885-020-07148-x
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.21492
[3]	中华人民共和国国家卫生健康委员会. 宫颈癌诊疗规范(2018年版)[J]. 肿瘤综合治疗电子杂志, 2020, 6(3):33-43. DOI: 10.12151/JMCM.2020.03-06. doi:10.12151/JMCM.2020.03-06
[4]	Dos Reis R, Andrade CEMC, Frumovitz M, et al. Radical hysterectomy and age: outcomes comparison based on a minimally invasive vs an open approach[J]. J Minim Invasive Gynecol, 2018, 25(7):1224-1230. DOI: 10.1016/j.jmig.2018.03.002. doi:10.1016/j.jmig.2018.03.002
[5]	Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer[J]. N Engl J Med, 2018, 379(20):1895-1904. DOI: 10.1056/NEJMoa1806395. doi:10.1056/NEJMoa1806395
[6]	许燕萍, 王志启, 梁旭东, 等. 局部晚期子宫颈癌患者腹腔镜与开腹手术的预后比较[J]. 中华妇产科杂志, 2020, 55(9):609-616. DOI: 10.3760/cma.j.cn112141-20200727-00612. doi:10.3760/cma.j.cn112141-20200727-00612
[7]	Levine MD, Brown J, Crane EK, et al. Outcomes of minimally invasive versus open radical hysterectomy for early stage cervical cancer incorporating 2018 FIGO staging[J]. J Minim Invasive Gynecol, 2020, 28(4):824-828. DOI: 10.1016/j.jmig.2020.07.021. doi:10.1016/j.jmig.2020.07.021
[8]	Saleh M, Virarkar M, Javadi S, et al. Cervical cancer: 2018 revised International Federation of Gynecology and Obstetrics staging system and the role of imaging[J]. AJR Am J Roentgenol, 2020, 214(5):1182-1195. DOI: 10.2214/AJR.19.21819. doi:10.2214/AJR.19.21819
[9]	杨东, 张洪文, 刘辉, 等. CT、MRI及正电子发射体层成像CT在宫颈癌诊断中的应用[J]. 国际肿瘤学杂志, 2014, 41(3):220-223. DOI: 10.3760/cma.j.issn.1673-422X.2014.03.019. doi:10.3760/cma.j.issn.1673-422X.2014.03.019
[10]	Balcacer P, Shergill A, Litkouhi B. MRI of cervical cancer with a surgical perspective: staging, prognostic implications and pitfalls[J]. Abdom Radiol (NY), 2019, 44(7):2557-2571. DOI: 10.1007/s00261-019-01984-7. doi:10.1007/s00261-019-01984-7
[11]	Merz J, Bossart M, Bamberg F, et al. Revised FIGO staging for cervical cancer-a new role for MRI[J]. Rofo, 2020, 192(10):937-944. DOI: 10.1055/a-1198-5729. doi:10.1055/a-1198-5729
[12]	Salvo G, Odetto D, Pareja R, et al. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: a review of gaps and questions that remain[J]. Int J Gynecol Cancer, 2020, 30(6):873-878. DOI: 10.1136/ijgc-2020-001257. doi:10.1136/ijgc-2020-001257
[13]	Salib MY, Russell JHB, Stewart VR, et al. 2018 FIGO staging classification for cervical cancer: added benefits of imaging[J]. Radiographics, 2020, 40(6):1807-1822. DOI: 10.1148/rg.2020200013. doi:10.1148/rg.2020200013
[14]	Jung W, Park KR, Lee KJ, et al. Value of imaging study in predicting pelvic lymph node metastases of uterine cervical cancer[J]. Radiat Oncol J, 2017, 35(4):340-348. DOI: 10.3857/roj.2017.00206. doi:10.3857/roj.2017.00206
[15]	Zhang X, Dong Y, Song Q, et al. The role of multiparametric magnetic resonance imaging in the study of primary tumor and pelvic lymph node metastasis in stage ⅠB1-ⅡA1 cervical cancer[J]. J Comput Assist Tomogr, 2020, 44(5):750-758. DOI: 10.1097/RCT.0000000000001084. doi:10.1097/RCT.0000000000001084
[16]	Mansoori B, Khatri G, Rivera-Colón G, et al. Multimodality imaging of uterine cervical malignancies[J]. AJR Am J Roentgenol, 2020, 215(2):292-304. DOI: 10.2214/AJR.19.21941. doi:10.2214/AJR.19.21941
[17]	Haldorsen IS, Lura N, Blaakór J, et al. What is the role of imaging at primary diagnostic work-up in uterine cervical cancer?[J]. Curr Oncol Rep, 2019, 21(9):77. DOI: 10.1007/s11912-019-0824-0. doi:10.1007/s11912-019-0824-0pmid:31359169
[18]	Zyla RE, Gien LT, Vicus D, et al. The prognostic role of horizontal and circumferential tumor extent in cervical cancer: implications for the 2019 FIGO staging system[J]. Gynecol Oncol, 2020, 158(2):266-272. DOI: 10.1016/j.ygyno.2020.05.016. doi:10.1016/j.ygyno.2020.05.016
[19]	Matsuo K, Machida H, Mandelbaum RS, et al. Validation of the 2018 FIGO cervical cancer staging system[J]. Gynecol Oncol, 2019, 152(1):87-93. DOI: 10.1016/j.ygyno.2018.10.026. doi:S0090-8258(18)31309-Xpmid:30389105
[20]	钟云. FIGO宫颈癌新分期系统的临床探讨[D]. 郑州: 郑州大学, 2020.
[21]	Ayhan A, Aslan K, Bulut AN, et al. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as ⅠB disease?[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 240:209-214.DOI: 10.1016/j.ejogrb.2019.07.002. doi:S0301-2115(19)30329-Xpmid:31325847
[22]	Fan Y, Wang MY, Mu Y, et al. Ovarian metastasis in women with cervical carcinoma in stages ⅠA to ⅡB: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(31):e21146. DOI: 10.1097/MD.0000000000021146. doi:10.1097/MD.0000000000021146
[23]	Nanthamongkolkul K, Hanprasertpong J. Predictive factors of pelvic lymph node metastasis in early-stage cervical cancer[J]. Oncol Res Treat, 2018, 41(4):194-198. DOI: 10.1159/000485840. doi:10.1159/000485840pmid:29562222
[24]	Pedone Anchora L, Carbone V, Gallotta V, et al. Should the number of metastatic pelvic lymph nodes be integrated into the 2018 Figo staging classification of early stage cervical cancer?[J]. Cancers (Basel), 2020, 12(6):1552. DOI: 10.3390/cancers12061552. doi:10.3390/cancers12061552
[25]	Li A, Wang L, Jiang Q, et al. Risk stratification based on metastatic pelvic lymph node status in stage ⅢC1p cervical cancer[J]. Cancer Manag Res, 2020, 12:6431-6439. DOI: 10.2147/CMAR.S253522. doi:10.2147/CMAR.S253522
[26]	Li C, Liu W, Cheng Y. Prognostic significance of metastatic lymph node ratio in squamous cell carcinoma of the cervix[J]. Onco Targets Ther, 2016, 9:3791-3797. DOI: 10.2147/OTT.S97702. doi:10.2147/OTT.S97702
[27]	Aslan K, Meydanli MM, Oz M, et al. The prognostic value of lymph node ratio in stage ⅢC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy[J]. J Gynecol Oncol, 2020, 31(1):e1. DOI: 10.3802/jgo.2020.31.e1. doi:10.3802/jgo.2020.31.e1
[28]	Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: current limitations and unanswered questions[J]. Gynecol Oncol, 2019, 152(1):202-207. DOI: 10.1016/j.ygyno.2018.10.007. doi:S0090-8258(18)31286-1pmid:30318103
[29]	徐红, 张静. 美国国立综合癌症网络《2020年宫颈癌临床实践指南》病理内容更新解读[J]. 中华病理学杂志, 2021, 50(1):9-13. DOI: 10.3760/cma.j.cn112151-20200712-00548. doi:10.3760/cma.j.cn112151-20200712-00548
[30]	刘成伟. 验证2018 FIGO宫颈癌新分期系统[D]. 南昌: 南昌大学, 2019.
[31]	Liu X, Wang J, Hu K, et al. Validation of the 2018 FIGO staging system of cervical cancer for stage Ⅲpatients with a cohort from China[J]. Cancer Manag Res, 2020, 12:1405-1410. DOI: 10.2147/CMAR.S239624. doi:10.2147/CMAR.S239624
[32]	Liu X, Wang W, Hu K, et al. A risk stratification for patients with cervical cancer in stage ⅢC1 of the 2018 FIGO staging system[J]. Sci Rep, 2020, 10(1):362. DOI: 10.1038/s41598-019-57202-3. doi:10.1038/s41598-019-57202-3
[33]	Grigsby PW, Massad LS, Mutch DG, et al. FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival[J]. Gynecol Oncol, 2020, 157(3):639-643. DOI: 10.1016/j.ygyno.2020.03.027. doi:S0090-8258(20)30252-3pmid:32248993